Long-Term Real-Life Efficacy and Safety of Repeated Ozurdex® Injections and Factors Associated with Macular Edema Resolution after Retinal Vein Occlusion: The REMIDO 2 Study

Ophthalmologica

Volumn 236, Issue 4, 2017, Pages 186-192

  Pommier, Stéphan ^a,c   Meyer, Franck ^a   Guigou, Sébastien ^a   Barthelemy, Tony ^a   Gobert, Fréderic ^a   Hajjar, Christian ^a   Merite, Pierre Yves ^a   Parrat, Eric ^a   Rouhette, Hervé ^a   Matonti, Fréderic ^a,b  

^a Collectif P15 ^*  (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Pays des Sorgues Ophthalmology Center   (France)

Author keywords

Dexamethasone; Intravitreal implant; Macular edema; Optical coherence tomography; Ozurdex injection; Ranibizumab; Retinal vein occlusion

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE; GLUCOCORTICOID;

AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAOCULAR HYPERTENSION; LONG TERM CARE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA TEAR; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; THERAPY DELAY; VISUAL ACUITY; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; RETINA; RETINAL VEIN OCCLUSION; TIME FACTOR; TREATMENT OUTCOME;

AGED; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85001837306     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000452896     Document Type: Article

References (24)

1. Yau JWY, Lee P, Wong TY, Best J, Jenkins A: Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008; 38: 904-910.
2. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-319.e1.
3. Laouri M, Chen E, Looman M, Gallagher M: The burden of disease of retinal vein occlusion: review of the literature. Eye Lond Engl 2011; 25: 981-988.
4. Haller JA, Bandello F, Belfort RJ, Blumenkranz MS, Gillies M, Heier J, et al: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460.
5. Haller JA, Bandello F, Belfort RJ, Blumenkranz MS, Gillies M, Heier J, et al: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.e3.
6. Hahn P, Fekrat S: Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 2012; 23: 175-181.
7. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, et al: Repeated intravitreal dexamethasone implant (Ozurdex ®) for retinal vein occlusion. Ophthalmologica 2013; 229: 21-25.
8. Matonti F, Meyer F, Guigou S, Barthelemy T, Dumas S, Gobert F, et al: Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol (Copenh) 2013; 91:e584-e586.
9. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A: Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye Lond Engl 2013; 27: 65-71.
10. Proença Pina J, Turki K, Labreuche J, Duhamel A, Tran THC: Efficacy and safety in retinal vein occlusion treated with at least three consecutive intravitreal dexamethasone implants. J Ophthalmol 2016; 2016: 6016491.
11. Bakri SJ, Omar AF, Iezzi R, Kapoor KG: Evaluation of multiple dexamethasone intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 2016; 36: 552-557.
12. Capone A, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, et al: Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 2014; 34: 342-351.
13. Augustin AJ, Kuppermann BD, Lanzetta P, Loewenstein A, Li X-Y, Cui H, et al: Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015; 15: 150.
14. Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, et al: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914.
15. Matonti F, Hoffart L, Baeteman C, Denis D: Repeated treatment for macular edema in vein occlusion by intravitreal implant of dexamethasone. Case Rep Ophthalmol 2012; 3: 339-342.
16. Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al: Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548.
17. Roth DB, Cukras C, Radhakrishnan R, Feuer WJ, Yarian DL, Green SN, et al: Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surg Lasers Imaging 2008; 39: 446-454.
18. Ip MS, Scott IU, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 Arch Ophthalmol 2009; 127: 1101-1114.
19. Scott IU, Ip MS, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127: 1115-1128.
20. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al: Longterm outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014; 121: 209-219.
21. Altunel O, Göktaş A, Duru N, Özköse A, Arifoǧlu HB, Ataş M: The effect of age on dexamethasone intravitreal implant (Ozurdex ®) response in macular edema secondary to branch retinal vein occlusion. Semin Ophthalmol 2016: 1-6.
22. Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, et al: Multicenter Ozurdex ®assessment for diabetic macular edema: MOZART study. J Fr Ophtalmol 2014; 37: 480-485.
23. Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, et al: Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2014; 24: 1-9.
24. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM: Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996; 103: 551-560.